Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease
Abstract
No abstract availableKeywords
Funding Information
- Northern Ontario Academic Medicine Association (A-14-10)
- Northern Ontario Academic Medicine Association (A-17-06)
- Pfizer
- Pfizer Canada
This publication has 44 references indexed in Scilit:
- Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind TrialClinical Infectious Diseases, 2013
- Serum IgM Antibodies Contribute to High Levels of Opsonophagocytic Activities in Toddlers Immunized with a Single Dose of the 9-Valent Pneumococcal Conjugate VaccineClinical and Vaccine Immunology, 2012
- Immune Response to Haemophilus influenzae Type b Vaccination in Patients with Chronic Renal FailureClinical and Vaccine Immunology, 2012
- Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B CellsThe Journal of Infectious Diseases, 2012
- Impact of More Than a Decade of Pneumococcal Conjugate Vaccine Use on Carriage and Invasive Potential in Native American CommunitiesThe Journal of Infectious Diseases, 2011
- A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine designNature Medicine, 2011
- Establishment of a New Human Pneumococcal Standard Reference Serum, 007spClinical and Vaccine Immunology, 2011
- Older Adults Have a Low Capacity To Opsonize Pneumococci Due to Low IgM Antibody Response to Pneumococcal VaccinationsInfection and Immunity, 2011
- Pneumococcal Capsular Polysaccharide Structure Predicts Serotype PrevalencePLOS Pathogens, 2009
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004